QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction

Clinical Cardiology

Volumn 33, Issue 3, 2010, Pages 132-138

  El Chami, Mikhael F ^a   Brancato, Candace ^b   Langberg, Jonathan ^a   Delurgio, David B ^a   Bush, Heather ^b,c   Brosius, Lynne ^b   Leon, Angel R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b REGISTRAT Inc   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; QRS COMPLEX; REGISTER; RISK FACTOR;

AGED; ANALYSIS OF VARIANCE; ATRIAL FIBRILLATION; BODY MASS INDEX; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77949732409     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20714     Document Type: Article

References (49)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293a-302.
2. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32(3): 695-703.
3. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429-1435.
4. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998;98(23):2574-2579.
5. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med. 1999;341(12):910-911.
6. Stevenson WG, Stevenson LW. Atrial fibrillation and heart failure - five more years. N Engl J Med. 2004;351(23):2437-2440.
7. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857-865.
8. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framinghamstudy. N Engl J Med. 1971;285(26):1441-1446.
9. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6): 421-428.
10. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5(2):167-173.
11. Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121(9):748-757.
12. Cohen-Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail. 2008;14(7):615-625.
13. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet. 2009;373(9657):82-93.
14. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin. 2009;27(1):13-24, vii.
15. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. New risk factors for atrial fibrillation: causes of "not-so-lone atrial fibrillation." Europace. 2008;10(6):668-673.
16. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J. 2008;29(13):1662- 1669.
17. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100(1):87-95.
18. Phang RS, Isserman SM, Karia D, et al. Echocardiographic evidence of left atrial abnormality in young patients with lone paroxysmal atrial fibrillation. Am J Cardiol. 2004;94(4):511-513.
19. Corell P, Gustafsson F, Schou M, et al. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail. 2007;9(3):258-265.
20. Parkash R, Maisel WH, Toca FM, et al. Atrial fibrillation in heart failure: highmortality risk even if ventricular function is preserved. Am Heart J. 2005;150(4):701-706.
21. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol. 2005;46(12): 2183-2192.
22. Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299(22):2656-2666.
23. Yerra L, Anavekar N, Skali H, et al. Association of QRS duration and outcomes aftermyocardial infarction: the VALIANT trial. Heart Rhythm. 2006;3(3):313-316.
24. De Winter O, Van de Veire N, Van Heuverswijn F, et al. Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction. Eur J Heart Fail. 2006;8(3):275-277.
25. Murkofsky RL, Dangas G, Diamond JA, et al. A prolonged QRS duration on surface electrocardiogram is a specific indicator of left ventricular dysfunction [see comment]. J Am Coll Cardiol. 1998;32(2):476-482.
26. Hanna IR, Heeke B, Bush H, Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006;3(8): 881-816.
27. Hanna IR, Heeke B, Bush H, The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006;47(8):1683-1688.
28. Galizio NO, Pesce R, Valero E, Which patients with congestive heart failure may benefit from biventricular pacing? Pacing Clin Electrophysiol. 2003;26(1 pt 2):158-161.
29. Grimm W, Sharkova J, Funck R, et al. How many patients with dilated cardiomyopathy may potentially benefit from cardiac resynchronization therapy? Pacing Clin Electrophysiol. 2003;26(1 pt 2):155-157.
30. Kalra PR, Sharma R, Shamim W, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol. 2002;86(2-3):225-231.
31. Kearney MT, Zaman A, Eckberg DL, et al. Cardiac size, autonomic function, and 5-year follow-up of chronic heart failure patients with severe prolongation of ventricular activation. J Card Fail. 2003;9(2):93-99.
32. Shenkman HJ, Pampati V, Khandelwal AK, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest. 2002;122(2):528-534.
33. Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. Am J Cardiol. 2004;93(2):244-246.
34. Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and totalmortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002;143(3):398-405.
35. Stellbrink C, Auricchio A, Diem B, et al. Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. Am J Cardiol. 1999;83(5B): 143D-150D.
36. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153(6):1021-1028.
37. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8(9):651-745.
38. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of theRate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2005;46(7):1298-1306.
39. Ruo B, Capra AM, Jensvold NG, Go AS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol. 2004;43(3):429-435.
40. Hanrahan JP, Grogan DR, Baumgartner RA, et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting β2-agonists arformoterol and salmeterol. Medicine (Baltimore). 2008;87(6):319-328.
41. Iguchi Y, Kimura K, Kobayashi K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol. 2008;102(8):1056-1059.
42. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity - results of a metaanalysis. Am Heart J. 2008;155(2):310-315.
43. Adam O, Neuberger HR, Bohm M, et al. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation. 2008;118(12):1285-1293.
44. Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009;53(1):24-29.
45. Bourassa MG. Angiotensin II inhibition and prevention of atrial fibrillation and stroke. J Am Coll Cardiol. 2005;45(5):720-721.
46. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45(4): 525-530.
47. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455-2461.
48. Mazzoleni A, Curtin ME, Wolff R, et al. On the relationship between heart weights, fibrosis, and QRS duration. J Electrocardiol. 1975;8(3):233-236.
49. Yamada T, Fukunami M, Ohmori M, et al. New approach to the estimation of the extent of myocardial fibrosis in patients with dilated cardiomyopathy: use of signal-averaged electrocardiography. Am Heart J. 1993;126(3 pt 1):626-631.